In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IsoTis NV

Division of Integra LifeSciences Holdings Corp.
www.isotis.com

Latest From IsoTis NV

Germany's Biotech Bust

Public markets around the world are down; Germany's Neuer Markt is also out. The demise of the exchange once hailed as Europe's most promising will hit more than just Germany's listed stocks. It affects the country's private sector, too, where young companies-and their investors-are frantically seeking ways to weather the storm.
BioPharmaceutical Europe

Deal Statistics Quarterly, Q3 2002

In Vivo presents another installment of our quarterly reivew of dealmaking--in this case July 2002-September 2002. Our data come from Windhover's Strategic Transactions Database. We include medical device financings by deal type; diagnostic financings by industry segment; pharma and biotech alliances by therapeutic category and industry segment; pharma and biotech financings by market segment, and pharma and biotech M&A.
BioPharmaceutical Medical Device

Isotis and Modex Take the Offensive

With market capitalizations below €40 million, both Modex and IsoTis have lost investors' attention, and have products too small to drive sufficient growth internally. Merging won't solve their size problems immediately, but it gives them a better chance of making the external acquisitions that neither could afford alone.
BioPharmaceutical Europe

Can France Stay in the Game?

The French government's efforts to encourage biotechnology have been modest and somewhat piecemeal. Yet two years ago, France's industry was nevertheless ranked second in Europe. Since then, the explosion of biotech companies in Germany, along with steady growth in other European markets, make the need for a coherent French strategy more urgent. France needs to take some bolder, more generous measures--particularly to reduce companies' tax burden and attract talent from overseas--without which it risks restricting itself to a small group of companies, many of whom will have to move elsewhere to grow substantially.
BioPharmaceutical Europe
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register